• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Effective in vitro delivery of paclitaxel by nanocargo of mesoporous polycaprolactone against triple negative breast cancer cells by minimalizing drug dose
【24h】

Effective in vitro delivery of paclitaxel by nanocargo of mesoporous polycaprolactone against triple negative breast cancer cells by minimalizing drug dose

机译：通过极小化药物剂量通过介孔聚己内酯的培养基聚己内酯的纳米曲线对三重阴性乳腺癌细胞进行有效递送紫杉醇的体外递送

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Among the breast cancers, triple negative breast cancer (TNBC) has relatively poor outcomes with a lower survival rate and personalised chemotherapy is the only option available for treatment. Currently in the biomedical domain, nanomaterials with porous morphology have revealed their tremendous possibilities to be used as a nanocarrier in treating cancer by offering void space to encapsulate/entrap biological agents. However, the development of nanocarrier-based targeted therapy with high therapeutic efficacy and fewer side effects to normal cells is always a challenge. Here, we have developed nanocargos based on biodegradable mesoporous PCL (polycaprolactone) of approx. diameter of 75 nm by template removal synthesis techniques. Succeeding the comparative analysis of the nanocarriers, the efficiencies of core shell PCL-mZnO (PZ) and mesoporous PCL (HPZ) to deliver paclitaxel (Taxol/T) into breast cancer cells, is investigated. We found that HPZ nanocapsules have less cytotoxicity and drug loading efficiency of about 600 μg mg ~(?1) . The Taxol-loaded nanoparticles (T-HPZ) have exhibited more cytotoxicity than Taxol alone treated cancer cells. Furthermore, T-HPZ treated MDA-MB231 cells are accumulated at G2/M phase of the cell cycle and eventually undergo apoptosis. In support of this, anchorage independent growth of MDA-MB231 cells are significantly inhibited by T-HPZ treatment. Together, our findings suggest that T-HPZ-based paclitaxel (Taxol/T) loaded nanoparticles provide a novel therapeutic option in the treatment of TNBC.
机译：在乳腺癌中，三重阴性乳腺癌（TNBC）具有较低的存活率和个性化疗的较低结果是唯一可用于治疗的选择。目前在生物医学领域，具有多孔形态的纳米材料揭示了它们通过提供空隙空间来包封/诱捕生物制剂来治疗癌症的巨大可能性。然而，基于纳米载体的靶向治疗的发展具有高治疗效果和较少的副作用对正常细胞略有挑战。这里，我们基于可生物降解的中孔PCL（聚己内酯）的纳米野核苷酸开发了大约。通过模板去除合成技术直径75nm。研究了纳米载体的比较分析，核心壳PCL-MZNO（PZ）和中孔PCL（HPZ）将紫杉醇（紫杉醇/ T）递送到乳腺癌细胞中的效率。我们发现HPZ纳米胶囊具有较少的细胞毒性和药物负载效率约为600μgmg〜（α1）。紫杉醇负载纳米颗粒（T-HPZ）表现出比紫杉醇单独处理的癌细胞更多的细胞毒性。此外，T-HPZ处理的MDA-MB231细胞累积在细胞周期的G2 / M阶段，最终经历凋亡。为了支持这一点，通过T-HPZ处理显着抑制MDA-MB231细胞的锚固自身生长。我们的研究结果表明，基于T-HPZ的紫杉醇（紫杉醇/ T）纳米颗粒在治疗TNBC提供了一种新的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号